Gabapentin Tablet
Product Images NDC 87441-036

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 87441-036). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 600 mg (8744103601 Gabapentin 600 mg)

Gabapentin Tablets, USP 600 mg oral tablets label from Unit Dose Solutions, Inc. The label includes dosage strength, storage instructions at controlled room temperature (20° to 25°C), dispensing instructions for pharmacists, and repackaging and distribution information. The label is for prescription use only.*

FDA Label Image

Equation (Equation)

A text panel displaying the formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine levels, and a factor for female patients. The formula is shown as CLCr = [(140 - age) × weight] / (72 × serum creatinine) with a 0.85 multiplier for females.*

FDA Label Image

Fig1 (Fig1)

A line graph showing the mean pain score over eight weeks comparing placebo and gabapentin (3600 mg/day). The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph indicates a decrease in pain score for gabapentin over time, while placebo scores remain relatively stable. The graph includes labels for a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Fig2 (Fig2)

A line graph depicting mean pain score over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Both Gabapentin doses show a reduction in mean pain score over time compared to placebo.*

FDA Label Image

Fig3 (Fig3)

A bar chart titled 'Proportion of Responders (patients with > 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares placebo (PBO) and gabapentin (GBP) at different dosages (3600 mg, 1800 mg, and 2400 mg) across two studies. Percentages of responders are shown on the vertical axis from 0% to 100%. Statistical significance markers are noted for some comparisons.*

FDA Label Image

Figure 4 (Fig4)

A scatter plot showing percentage difference versus daily dose (mg) for Gabapentin tablets in three studies labeled a, b, and c. The x-axis represents daily dose ranging from 600 to 1800 mg, and the y-axis shows difference in percent from 2 to 22%. Data points for each study are plotted and labeled accordingly.*

FDA Label Image

Molecula Formula Gabapentin (Structure)

Chemical structure of the active ingredient gabapentin, showing a cyclohexane ring bonded to an amino group and a carboxyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.